Lineage Cell Therapeutics, Inc. (LCTX)

Lineage Cell Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	10.91	9.5	8.95	14.7	4.34	1.83
Revenue Growth (YoY)	76.43%	6.19%	-39.16%	238.70%	137.73%	-48.05%
Cost of Revenue	13.08	12.81	16.38	0.73	1.43	0.39
Gross Profit	-2.17	-3.31	-7.43	13.98	2.92	1.44
Selling, General & Admin	18.23	18.17	13.77	22.51	18.21	15.57
Research & Development	-	-	-	13.99	33.91	12.32
Operating Expenses	18.23	18.17	13.77	36.5	52.13	27.89
Operating Income	-20.4	-21.48	-21.2	-22.52	-49.21	-26.45
Interest & Investment Income	1.72	1.72	1.63	0.83	0	1.04
Currency Exchange Gain (Loss)	1.61	-0.57	-1.04	-2	1.49	2.88
Other Non Operating Income (Expenses)	-8.86	1.76	0.54	0.07	0.21	-0.17
EBT Excluding Unusual Items	-25.92	-18.57	-20.08	-23.62	-47.52	-22.7
Gain (Loss) on Sale of Investments	-	-0.01	-0.18	-2.19	3.73	0.78
Legal Settlements	-	-	-3.53	-	-	-
Other Unusual Items	-	-	0.5	-	0.52	-
Pretax Income	-40.76	-18.58	-23.28	-25.81	-43.27	-21.92
Income Tax Expense	-	-	-1.8	0.54	-	-1.24
Earnings From Continuing Operations	-40.76	-18.58	-21.48	-26.35	-43.27	-20.69
Minority Interest in Earnings	-0.15	-0.03	-0.01	0.08	0.25	0.04
Net Income	-40.91	-18.61	-21.49	-26.27	-43.02	-20.65
Net Income to Common	-40.91	-18.61	-21.49	-26.27	-43.02	-20.65
Shares Outstanding (Basic)	221	200	173	170	165	150
Shares Outstanding (Diluted)	221	200	173	170	165	150
Shares Change (YoY)	22.42%	15.94%	1.69%	3.22%	9.64%	3.10%
EPS (Basic)	-0.19	-0.09	-0.12	-0.15	-0.26	-0.14
EPS (Diluted)	-0.19	-0.09	-0.12	-0.15	-0.26	-0.14
Free Cash Flow	-23.15	-23.66	-29.24	0.65	-23.9	-19.82
Free Cash Flow Per Share	-0.10	-0.12	-0.17	0.00	-0.14	-0.13
Gross Margin	-19.86%	-34.81%	-83.07%	95.05%	67.15%	78.92%
Operating Margin	-186.87%	-226.11%	-237.04%	-153.17%	-1133.63%	-1448.36%
Profit Margin	-374.84%	-195.91%	-240.20%	-178.69%	-990.99%	-1130.83%
Free Cash Flow Margin	-212.08%	-249.05%	-326.89%	4.39%	-550.59%	-1085.27%
EBITDA	-19.77	-20.87	-20.51	-21.79	-48.34	-24.41
EBITDA Margin	-181.13%	-219.70%	-229.30%	-148.22%	-	-
D&A For EBITDA	0.63	0.61	0.69	0.73	0.87	2.04
EBIT	-20.4	-21.48	-21.2	-22.52	-49.21	-26.45
EBIT Margin	-186.87%	-226.11%	-237.04%	-153.17%	-	-
Revenue as Reported	10.91	9.5	8.95	14.7	4.34	1.83

Updated May 13, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q